**Question:** About osteogenesis imperfecta: all are true except:

A. Osteogenesis imperfecta (OI) is a genetic disorder caused by mutations in COL1A1 or COL1A2 genes, which encode for type I collagen.
B. This disorder is mainly characterized by fractures, blue sclera, and short stature.
C. Treatment options for OI primarily include pain management and physical therapy.
D. Osteogenesis imperfecta is a rare condition affecting only 1 in 10,000 live births.

**Correct Answer:** .

**Core Concept:**
Osteogenesis imperfecta (OI) is a genetic disorder characterized by defective type I collagen production due to mutations in COL1A1 or COL1A2 genes. Type I collagen is a major constituent of connective tissue, which provides strength and resilience to bones, skin, and other tissues. OI leads to fragile bones prone to fractures, blue sclera (ocular involvement), and short stature.

**Why the Correct Answer is Right:**
Option A is incorrect because it mentions that OI is a rare condition affecting only 1 in 10,000 live births. In reality, OI is not that rare; it affects around 1 in 15,000-20,000 individuals worldwide.

**Why Each Wrong Option is Incorrect:**

A. This statement is incorrect because OI is mainly characterized by fractures, blue sclera, and short stature, which are the cardinal features of the disease.

B. This statement is incorrect because while pain management and physical therapy are essential for OI patients, they are not the primary treatment options. Bone marrow transplantation, gene therapy, and bisphosphonates are novel treatments that are currently being explored for OI patients.

**Clinical Pearl:**
Osteogenesis imperfecta is a complex and multifaceted disorder with diverse clinical presentations, depending on the severity and type of the disease. Adequate understanding of the disease features and management is crucial for healthcare professionals providing care to OI patients.